期刊
LABORATORY MEDICINE
卷 49, 期 2, 页码 134-139出版社
OXFORD UNIV PRESS
DOI: 10.1093/labmed/lmx084
关键词
circulating tumor cells; biomarkers; ovarian cancer; ovarian mass; pelvic mass; Krukenberg tumors
资金
- NIH Clinical and Translational Science KL2 Scholar Award [8UL1TR000114]
- Litman Family Fund for Cancer Research
- University of Minnesota Deborah E. Powell Center for Women's Health Interdisciplinary Seed Grant [PCWH-2013-002]
- Minnesota Masonic Charities
- Masonic Cancer Center [P30 CA77598]
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055887] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002494] Funding Source: NIH RePORTER
Background: The clinical assessment of circulating tumor cells (CTCs) as a blood-based biomarker is FDA-approved for use in breast, colorectal, and prostate cancers. The objective of this prospective clinical study was to determine whether pretreatment CTCs are a useful diagnostic biomarker in women with complex pelvic masses. Methods: Whole blood was collected from 49 women with newly diagnosed pelvic masses. The presence of CTCs was compared between women with and without ovarian cancer histopathologic diagnosis after surgery using a Chi-squared test. Results: CTCs were absent in those with benign disease (0/14), present in 17% (5/29) of patients with a histologic diagnosis of ovarian carcinoma, and present in 80% (4/5) of patients with ovarian metastases from other cancers (P = 0.001). All 5 women with ovarian cancer who had CTCs present presented stage III or IV of the disease (P = 0.13). Conclusions: CTCs were more prevalent in patients with metastases to the ovary than in primary ovarian carcinomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据